Skip to content

Efficacy of Melatonin in Burning Mouth Syndrome (BMS)

Melatonin to Treat Burning Mouth Syndrome (BMS): A Randomized, Cross-over, Placebo-controlled, Triple-blind Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02580734
Acronym
BMS2013
Enrollment
20
Registered
2015-10-20
Start date
2014-03-31
Completion date
2015-10-31
Last updated
2015-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burning Mouth Syndrome

Keywords

burning mouth syndrome, treatment, oral chronic pain

Brief summary

The purpose of this study is to determine whether melatonin is effective in the treatment of burning mouth syndrome (BMS).

Detailed description

This is a crossover trial involving a total of 20 patients with Burning Mouth Syndrome, considered a chronic neuropathic pain. In two consecutive treatment periods, both 8 week long, each patient receives externally indistinguishable capsules (placebo or melatonin). A 4 weeks wash-out period is applied, between these two periods. The capsules contain either placebo or 3 mg-melatonin (4 time/day for a total of 12 mg/day of melatonin). The primary endpoint is the change in pain intensity at the end of each treatment period, measured using VAS, verbal intensity score and NRS, as well as number of oral sites affected by the burning sensation. Furthermore, data from quality of life, anxiety and sleep questionnaires are collected (sf-36, HAM-A, ESS, MOS). Adverse effects are carefully recorded as well as blood samples, in order to measure serum melatonin levels during the trial.

Interventions

DIETARY_SUPPLEMENTmelatonin

Cross-over randomized clinical trials

Sponsors

University of Milan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* patients over 18 yrs suffering from burning mouth syndrome

Exclusion criteria

* epilepsy * pregnancy * concomitant treatment with melatonin * concomitant anticoagulants * night time working persons

Design outcomes

Primary

MeasureTime frame
Reduction/resolution of symptoms in BMSwithin the first 60 days

Secondary

MeasureTime frame
improvement in quality of lifewithin the first 60 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026